PharmacoEconomics Italian Research Articles

, Volume 10, Issue 1, pp 37–47

Costo efficacia di peginterferone α-2a + ribavirina versus peginterferone α-2b + ribavirina nel trattamento dell’epatite cronica di tipo C in pazienti HIV co-infetti


Cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin in the treatment of chronic hepatitis C in HIV-HCV co-infection


Introduction: The objective of this study was to evaluate the cost-effectiveness of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin in the treatment of chronic hepatitis C in HIV-HCV co-infection.

Methods: We used a pre-existent Markov model of disease progression in which two cohorts of patients received peginterferon α-2a plus ribavirin or peginterferon α-2b plus ribavirin for 48 weeks and were followed for their expected lifetimes. The reference patient was a 40-year-old man or woman. The sustained virological response (SVR) with peginterferon α-2a plus ribavirin and peginterferon α-2b plus ribavirin, were taken from two different publications. Utilities and costs for each health state were based on literature estimates and on Italian treatment patterns. Costs in 2005 euros and benefits were discounted at 3%. Sensitivity analyses on key clinical and economic parameters were performed. The analysis was conducted from the perspective of the Italian National Health Service.

Results: For the two cohorts, expected life-years with peginterferon α-2a plus ribavirin versus peginterferon α-2a plus ribavirin were respectively 24.47 and 23.71 years. Quality-adjusted life years for peginterferon α-2a plus ribavirin were 12.93, and 12.49 for peginterferon α-2b plus ribavirin. The expected cost was € 19,858 with peginterferon α-2a plus ribavirin and €19,983 with peginterferon α-2b plus ribavirin.

Conclusion: This economic evaluation suggests that peginterferon α-2a plus ribavirin is a dominant strategy versus peginterferon α-2b plus ribavirin for treatment of adults with HIV-HCV co-infection, under some assumptions regarding treatment effectiveness and model structure.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in confection. Am J Med 1999; 107: 79S–84PubMedCrossRefGoogle Scholar
  2. 2.
    Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, et al. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999; 31: 119–23PubMedCrossRefGoogle Scholar
  3. 3.
    Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33: 365–72PubMedCrossRefGoogle Scholar
  4. 4.
    Thomas DL, Shih JW, Alter HJ, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174: 690–5PubMedCrossRefGoogle Scholar
  5. 5.
    Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998; 279: 930–7PubMedCrossRefGoogle Scholar
  6. 6.
    Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997; 337: 725–33PubMedCrossRefGoogle Scholar
  7. 7.
    Bräu N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17: 2279–90PubMedCrossRefGoogle Scholar
  8. 8.
    Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813–28PubMedCrossRefGoogle Scholar
  9. 9.
    Kuehne F, Bethe U, Freedberg K, et al. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002; 162: 2545–56PubMedCrossRefGoogle Scholar
  10. 10.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82PubMedCrossRefGoogle Scholar
  11. 11.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65PubMedCrossRefGoogle Scholar
  12. 12.
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55PubMedGoogle Scholar
  13. 13.
    Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228–37PubMedCrossRefGoogle Scholar
  14. 14.
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996: 24: 289–93PubMedCrossRefGoogle Scholar
  15. 15.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–50PubMedCrossRefGoogle Scholar
  16. 16.
    Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. A randomized controlled trial. JAMA 2004; 292: 2839–48PubMedCrossRefGoogle Scholar
  17. 17.
    Salomon J, Weinstein M, Hammitt J, et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156: 761–73PubMedCrossRefGoogle Scholar
  18. 18.
    Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996; 23: 1117–25PubMedCrossRefGoogle Scholar
  19. 19.
    Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997; 27: 201–5PubMedCrossRefGoogle Scholar
  20. 20.
    Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65PubMedGoogle Scholar
  21. 21.
    De Jongh F, Jannsen H, de Man R, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630–5PubMedGoogle Scholar
  22. 22.
    Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240–3PubMedGoogle Scholar
  23. 23.
    Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273–81PubMedCrossRefGoogle Scholar
  24. 24.
    Surveillance and Epidemiology End Results Program Seer*Stat public-use files. Bethesda, MD: National Cancer Institute, 2003Google Scholar
  25. 25.
    Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889–96PubMedCrossRefGoogle Scholar
  26. 26.
    Jaggy C, von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362: 877–8PubMedCrossRefGoogle Scholar
  27. 27.
    Munari LM, Picciotto A. Recombinant interferon α-2b therapy of chronic hepatitis C in Italy: an economic analysis. Forum Trends Exp Clin Med 1996; 6: 347–53Google Scholar
  28. 28.
    Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. (Ed. it. a cura di Fattore G, Garattini L, Lucioni C). Metodi per la valutazione economica dei programmi sanitari. Roma: Il Pensiero Scientifico Editore, 2000Google Scholar
  29. 29.
    Weinstein MC, Fineberg HV. L’analisi della decisione in medicina clinica. Milano: Fondazione Smith Kline FrancoAngeli, 1984Google Scholar

Copyright information

© Adis Data Information 2008

Authors and Affiliations

  1. 1.Wolters Kluwer Health, Adis International LtdMilanoItaly

Personalised recommendations